Santa Ana Bio is focused on developing precision medicines for immune-mediated diseases by utilizing advanced multi-omics platforms and antibody engineering. Their approach emphasizes a deep understanding of the cellular and immune pathways involved in autoimmune and inflammatory conditions, which enables the creation of targeted therapies. This strategy aims to move beyond traditional methods that broadly neutralize cytokines, which often lead to unwanted side effects, by instead developing therapeutics that specifically target and suppress pathogenic cells and pathways.

The company is advancing several novel therapeutics, including monoclonal antibodies, bi-specific antibodies, and antibody-drug conjugates (ADCs). Notably, their candidate SAB01 selectively inhibits c-Kit on mast cells, addressing toxicity issues associated with this target by conditionally blocking it in the presence of a specific anchor target. Additionally, SAB03 is designed to modulate PD-1 in a way that effectively suppresses various pathogenic T cells, while SAB05 employs a unique technology for antibody-glucocorticoid conjugates, allowing for the therapeutic benefits of glucocorticoids without the associated side effects. These innovative approaches position Santa Ana Bio to make significant advancements in the treatment of serious immune-mediated diseases.

United States

Santa Ana Bio is a precision immunology company leveraging multi-omics platforms and antibody engineering to deliver targeted therapies to patients with autoimmune and inflammatory diseases.

Santa Ana Bio

Company Details